Treatment of Adult Dermatomyositis in Chronic IIM-Associated Interstitial Lung Disease

Adult dermatomyositis presenting with chronic interstitial lung disease (ILD) as part of idiopathic inflammatory myopathy (IIM) poses a distinct clinical challenge. The pulmonary involvement can drive overall prognosis and requires a targeted treatment strategy beyond standard myositis management.

Clinical Scenario

This protocol is specific to adult patients with dermatomyositis complicated by chronic IIM-associated interstitial lung disease — a recognised and clinically significant extra-muscular manifestation in this population.

Treatment Approach (Partial Overview)

When chronic ILD in this setting proves resistant to initial management, specific pharmacological agents are indicated. The full protocol details which agents apply, under what criteria, and how they are sequenced.

Complete agent selection, decision criteria, and the full clinical algorithm are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

In the treatment of chronic IIM-associated interstitial lung disease:

Rituximab or cyclophosphamide is to be considered in treatment-resistant patients.

DOI: 10.1093/rheumatology/keac115

View source ↗